entertainment -WSS

entertainment

author：knowledge 2025-10-04 07:15:33 - browse：34221

Eli Lilly headquarters — Kristoffer Tripplaar/AP

Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Gene editing the human germline: What are the risks?

focus

WSS

Congenital heart disease patients face new threat of heart failure

Colonoscopy prep: Liquid

What causes an itch? Researchers may have solved the mystery

Future doctors should be trained to promote social change

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Patients' immediate access to test results puts radiologists in a bind

focus

entertainment

hotspot

Drug repurposing or repositioning? The language matters

Radiology is caught between AI's potential and concern for patients

Jerome Adams on the need for new antivirals for Covid

Future doctors should be trained to promote social change

Medical leaders decry Supreme Court decision on affirmative action

Why sickle cell disease is getting the first CRISPR treatment

Heart attack and stroke risk calculators need revising

Congenital heart disease patients face new threat of heart failure

George Santos makes 1st court appearance after pleading not guilty to 13 counts

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

explore

What causes an itch? Researchers may have solved the mystery

What PEPFAR has meant on the ground in Ukraine

Virtual Event: March of the Biosimilars

Teach medical students about patients with intellectual disabilities

Stop the failed accountable care organization experiment

Nurses recount patients attacks

focus

focus

hotspot

knowledge